{
    "organizations": [],
    "uuid": "f97877091571e817cefd9c711680f50a15cfe7cf",
    "author": "",
    "url": "https://www.reuters.com/article/brief-fda-rejects-filing-for-celgene-ms/brief-fda-rejects-filing-for-celgene-ms-drug-idUSASB0C7UO",
    "ord_in_thread": 0,
    "title": "BRIEF-FDA rejects filing for Celgene MS drug",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 27 (Reuters) - Celgene Corp:\n* CELGENE PROVIDES REGULATORY UPDATE ON OZANIMOD FOR THE TREATMENT OF RELAPSING MULTIPLE SCLEROSIS\n* CELGENE CORP - ‍FDA DETERMINED NONCLINICAL AND CLINICAL PHARMACOLOGY SECTIONS IN NDA WERE INSUFFICIENT TO PERMIT A COMPLETE REVIEW​\n* CELGENE - CO INTENDS TO SEEK IMMEDIATE GUIDANCE, INCLUDING REQUESTING A TYPE A MEETING WITH FDA\n* CELGENE - GOT REFUSAL TO FILE LETTER FROM FDA ABOUT CO‘S NDA FOR OZANIMOD IN DEVELOPMENT FOR TREATING PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS\n* CELGENE - ‍SEEKING GUIDANCE WHICH INCLUDES REQUESTING MEETING WITH FDA, TO ASCERTAIN WHAT ADDITIONAL DATA WILL BE REQUIRED TO RESUBMIT NDA​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-28T00:12:00.000+02:00",
    "crawled": "2018-02-28T00:34:18.026+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "celgene",
        "corp",
        "celgene",
        "provides",
        "regulatory",
        "update",
        "ozanimod",
        "treatment",
        "relapsing",
        "multiple",
        "sclerosis",
        "celgene",
        "corp",
        "determined",
        "nonclinical",
        "clinical",
        "pharmacology",
        "section",
        "nda",
        "insufficient",
        "permit",
        "complete",
        "celgene",
        "co",
        "intends",
        "seek",
        "immediate",
        "guidance",
        "including",
        "requesting",
        "type",
        "meeting",
        "fda",
        "celgene",
        "got",
        "refusal",
        "file",
        "letter",
        "fda",
        "co",
        "nda",
        "ozanimod",
        "development",
        "treating",
        "patient",
        "relapsing",
        "form",
        "multiple",
        "sclerosis",
        "celgene",
        "guidance",
        "includes",
        "requesting",
        "meeting",
        "fda",
        "ascertain",
        "additional",
        "data",
        "required",
        "resubmit",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}